LEVOCARNITINE Drug Patent Profile

Which patents cover Levocarnitine, and when can generic versions of Levocarnitine launch?

Levocarnitine is a drug marketed by Am Regent, Deva Holding As, Hikma, Teva Pharms Usa, Novitium Pharma, Rising, and Sciegen Pharms. and is included in ten NDAs.

The generic ingredient in LEVOCARNITINE is levocarnitine. There are four drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the levocarnitine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Levocarnitine

A generic version of LEVOCARNITINE was approved as levocarnitine by HIKMA on March 29^th, 2001.

Summary for LEVOCARNITINE

US Patents:	0
Applicants:	7
NDAs:	10
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	82
Clinical Trials:	26
Patent Applications:	2,601
Drug Prices:	Drug price information for LEVOCARNITINE
What excipients (inactive ingredients) are in LEVOCARNITINE?	LEVOCARNITINE excipients list
DailyMed Link:	LEVOCARNITINE at DailyMed

See drug prices for LEVOCARNITINE

Recent Clinical Trials for LEVOCARNITINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	EARLY_PHASE1
Shaikh Zayed Hospital, Lahore	PHASE4
Children's Oncology Group	Phase 3

See all LEVOCARNITINE clinical trials

Pharmacology for LEVOCARNITINE

Drug Class

Carnitine Analog

Anatomical Therapeutic Chemical (ATC) Classes for LEVOCARNITINE

A16AA	Amino acids and derivatives
A16A	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A	Alimentary tract and metabolism

US Patents and Regulatory Information for LEVOCARNITINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Am Regent	LEVOCARNITINE	levocarnitine	INJECTABLE;INJECTION	075861-001	Jun 22, 2001	AP	RX	No	No
Rising	LEVOCARNITINE	levocarnitine	SOLUTION;ORAL	076851-001	Aug 10, 2004	AA	RX	No	No
Teva Pharms Usa	LEVOCARNITINE	levocarnitine	INJECTABLE;INJECTION	075881-001	Mar 29, 2001		DISCN	No	No
Sciegen Pharms	LEVOCARNITINE	levocarnitine	SOLUTION;ORAL	212533-001	Nov 10, 2021	AA	RX	No	No
Deva Holding As	LEVOCARNITINE	levocarnitine	INJECTABLE;INJECTION	217430-001	Jun 30, 2025	AP	RX	No	No
Hikma	LEVOCARNITINE	levocarnitine	INJECTABLE;INJECTION	075567-001	Mar 29, 2001	AP	RX	No	No

Market Overview and Financial Trajectory of Levocarnitine

Last updated: February 13, 2026

Levocarnitine, a bioequivalent form of L-carnitine, is primarily used to treat conditions related to carnitine deficiency such as primary and secondary carnitine deficiency, certain mitochondrial disorders, and to aid in managing heart failure and other metabolic disorders. Its market dynamics are shaped by regulatory approvals, clinical efficacy, manufacturing capacity, and competition from alternative products.

Global Market Size and Growth Trends

The global levocarnitine market is projected to grow at a compound annual growth rate (CAGR) of approximately 6-8% from 2022 through 2028. The market was valued at roughly $300 million in 2022, with key drivers including increasing prevalence of metabolic disorders, expanding clinical applications, and rising awareness among healthcare providers.

Key Market Segments

Segment	Details	Market Share (2022)	Growth Drivers
End-Use Application	Dietary supplements, clinical treatments, functional foods	50%	Rising demand for health supplements, aging population
Geographic Region	North America, Europe, Asia-Pacific, Rest of World	North America: 35%	Increased healthcare spending, higher diagnosed rates
Formulation	Oral tablets, capsules, injectable solutions	Oral tablets: 65%	Convenience, patient compliance

Competitive Landscape

Major producers include:

• Abbott Laboratories: Offers Levocarnitine products for clinical use with global distribution channels.
• Shandong Lujian Pharmaceutical: Supplies bulk levocarnitine formulations, primarily serving Asian markets.
• Roche and Pfizer: Historically involved in formulations for metabolic disorders.

Emerging players focus on biosimilar and generic formulations, aiming to reduce costs and expand access.

Regulatory Environment

The US Food and Drug Administration (FDA) considers levocarnitine a dietary supplement and an approved drug for indicated uses. The European Medicines Agency (EMA) has approved levocarnitine for similar indications within the EU. Regulatory approval timelines influence market entry and expansion potential.

Financial Projections and Investment Opportunities

• Revenue Growth: Estimated to reach $500 million globally by 2028, driven by expansion in Asian and emerging markets.
• R&D Investment: Pharmaceutical companies are investing in clinical trials to expand indications, including mitochondrial and metabolic disorders [1].
• Pricing Dynamics: Oral formulations retail between $15-$50 for a month’s supply, depending on formulation and region.

Challenges Impacting Market and Financials

• Competition from Alternative Therapies: Coenzyme Q10, L-carnitine formulations, and newer mitochondrial-targeted drugs can reduce market share.
• Stringent Regulatory Approval Processes: Delays or restrictions affect new product launches and clinical use expansion.
• Pricing Pressure: Especially in healthcare systems with tighter budgets, affecting profit margins.

Future Outlook

The future of levocarnitine hinges on:

• Demonstrating efficacy in novel indications such as neurodegenerative diseases.
• Diversifying formulations to meet patient preferences.
• Strengthening manufacturing capacity to address global demand.
• Navigating regulatory pathways for broader indications.

Key Takeaways

• Market growth is driven by increased use in metabolic and mitochondrial disorders.
• The product’s value is contingent on clinical evidence and regulatory status.
• Competition from generics and alternative therapies remains a challenge.
• Expansion in Asian markets and ongoing R&D investments are critical growth factors.
• Pricing varies based on formulation, region, and healthcare system constraints.

FAQs

1. What are the main therapeutic applications of levocarnitine?

It treats primary and secondary carnitine deficiency, supports mitochondrial function, and manages heart failure associated with metabolic deficiencies.

2. Which regions are experiencing the fastest growth in levocarnitine demand?

Asia-Pacific and Latin America are experiencing rapid growth due to rising healthcare infrastructure and increasing awareness of metabolic disorders.

3. How does regulatory approval impact market revenues?

Approval facilitates product commercialization, expands indications, and enhances investor confidence, directly influencing market size and profitability.

4. What factors are most likely to influence future pricing trends?

Generic competition, manufacturing efficiencies, and healthcare system budgets will influence pricing.

5. Are there ongoing clinical trials expanding levocarnitine’s indications?

Yes, trials exploring neuroprotective effects and mitochondrial disorders are ongoing, which could unlock new markets.

---

References

[1] Market Research Future, "Global Levocarnitine Market Analysis," 2022.